Back to results
US 2026/0191926 A1Published application
MC4 Antagonists in the Treatment of Restless Legs Syndrome
OwnerBrian Kooinventor
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating restless leg syndrome (RLS). The methods include administering to a subject a pharmaceutical composition containing an MC4 antagonist or a pharmaceutically acceptable salt thereof.
Claims20
A method of treating, preventing, or ameliorating restless leg syndrome (RLS) in a subject in need thereof, the method comprising:
- administering to the subject a therapeutically effective amount of an MC4 antagonist or a pharmaceutically acceptable salt thereof, which is optionally formulated as a pharmaceutical composition further comprising at least one pharmaceutically acceptable carrier or excipient.
A method of reducing or eliminating symptoms associated with RLS in a subject in need thereof, the method comprising:
- administering to the subject a therapeutically effective amount of an MC4 antagonist or a pharmaceutically acceptable salt thereof, which is optionally formulated as a pharmaceutical composition further comprising at least one pharmaceutically acceptable carrier or excipient.
A method of treating, preventing, or ameliorating augmentation associated with prior treatment of RLS in a subject in need thereof, the method comprising:
- administering to the subject a therapeutically effective amount of an MC4 antagonist or a pharmaceutically acceptable salt thereof, which is optionally formulated as a pharmaceutical composition further comprising at least one pharmaceutically acceptable carrier or excipient;
- wherein the prior treatment is a previously administered dopamine agonist to the subject.
Dependencies are inferred from the claim text.